Roche Romania seeks clarification for higher clawback tax

Ovidiu Posirca 10/05/2017 | 12:18

Drugs maker Roche Romania says that the value of the clawback tax has climbed “inexplicably” in the first quarter of this year to 19.86 percent compared to the end of last year, although the market for prescription based drugs fell by 11 percent.

Roche says it has asked public authorities once again to check the data of the National Health Insurance House (CNAS) with the help on an independent auditor.

“We look into any legal move deemed necessary to verify the accuracy of the data, including discussions with relevant investigation authorities. We want to make sure that the data based on which the clawback tax is computed are correct and communicated in a transparent manner,” said Martine Draullette, general manager of Roche Romania.

The clawback tax is paid producers based on the value of the drugs disbursed by the state. Although the tax was rolled out in 2009, as a temporary measure due to the financial crisis, it has been enforced to date.

Roche calls on authorities to launch a new mechanism through which each side contributes to the financing of the real consumption of drugs in Romania.

The company said that the public budget for drugs needs additional funds because its level has been frozen since 2012.

BR Magazine | Latest Issue

Download PDF or read online: December 2022 Issue | Business Review Magazine

The December 2022 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “Xclusiverse: Going Beyond the Traditional Ways of Doing Business.”
Ovidiu Posirca | 19/12/2022 | 18:45

    You will receive a download link for the latest issue of Business Review Magazine in PDF format, based on the completion of the form below.

    I agree with the Privacy policy of business-review.eu
    I agree with the storage and handling of my data by business-review.eu
    Advertisement Advertisement
    Close ×

    We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

    Accept & continue